NCT04597671View on ClinicalTrials.gov

Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2032

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Durvalumab

Durvalumab is used as standard of care

RADIATION

low-dose PCI

PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions

Trial Locations (14)

Unknown

ZGT, Almelo

AmsterdamUMC - location VUmc, Amsterdam

Radiotherapie Groep, Arnhem

Rijnstate, Arnhem

Gelderse Vallei, Ede

Catharina Ziekenhuis, Eindhoven

ZRTI, Flushing

UMCG, Groningen

Canisius Wilhemina Ziekenhuis, Nijmegen

Radboud UMC, Nijmegen

ZorgSaam Ziekenhuis, Terneuzen

Maxima Medisch Centrum, Veldhoven

Zaans Medisch Centrum, Zaandam

5912 BL

Maastro, Maastricht

All Listed Sponsors
lead

Association NVALT Studies

OTHER